Washington, DC, USA – While the United States is promoting its COVID-19 inoculation, Aiming to deliver vaccines to all adults by 19 April, Some physicians and health workers have expressed concern that brand choices among potential vaccine recipients could hurt efforts to slow the spread of the virus.
Many states across the country are continuing their efforts to vaccinate people as soon as possible Soothe new waves of infection. As of Wednesday, the United States had administered more than three million doses nationwide on average in the last seven days, according to data from Our World. Earlier this week, more than four million people in one million received shots, a record high number of injections per day.
The U.S. Food and Drug Administration (FDA) has approved the urgent use of three CVID-19 vaccines, which it says are highly effective in preventing coronavirus infections and serious illness.
United States Johnson and Johnson vaccines have been approved Towards the end of February after the approval of the Pfizer and Moderna vaccines last December. The J&J vaccine requires a single shot, the others are given in two doses. Each must be stored at a different temperature.
The FDA found that all three vaccines provide almost complete protection against COVID-19-related deaths and hospitalizations. However, in clinical trials, Pfizer and Moderna vaccines have reported about 95 percent efficacy in preventing mild illness from the virus, and J&J reported Efficiency 72 percent In his US judgment.
As the rollout of the vaccine has accelerated, some health workers have seen more patients prioritize vaccination with specific vaccines.
Last month, Detroit Mayor Mike Dugan said he preferred the townspeople to receive the Pfizer and Moderna vaccines.
“Johnson & Johnson is a very good vaccine. Moderna and Pfizer are the best. And I’m doing my best to make sure that Detroit residents get the best, “he said. Duggan said in early March.
After the backlash, he said the city would make the J&J vaccine part of its vaccine.
Public health experts say the difference in efficacy is not as recommended as the number. These trials were conducted at different times with the emergence of newer, more contagious forms of coronaviruses during the testing of the J and J vaccines.
Moreover, the J&J vaccine has shown a 85 percent effectiveness Its US testing prevents serious illness, according to the FDA.
But Johnson and Johnson may realize this is less effective than other vaccines. A CNBC poll last month found that 8 percent of respondents would wait until they found a choice for their vaccine brand.
Dr. Robert C. Gallo, Director and Co-Founder of the Institute of Human Virology (IHV), University of Maryland School of Medicine Global Virus Network (GVN)He said he was indifferent to what vaccine he had received when he was insulated about a month ago.
Gallo told Al Jazeera, “I didn’t care about any of this because it’s very similar to what it was approved for in the United States – from the statistics available -” Gallo told Al Jazeera.
“My wife and I just went and got what we had. We didn’t even think twice which one it was because the results between these three are quite comparable. “
Gallo told Al Jazeera that he understands that some people may want to take the best vaccine available, but can’t wait to get the shot that looks good.
He said the 722 percent efficacy rate was “horribly good”, noting that flu shot efficacy could be less than 30 percent in certain years, but people should still take it.
“I won’t wait because I think the chances of any vaccine getting infected are very good, especially in a few places in the world, including a few states in the United States.”
Gallo said he was “concerned” that people who decided to delay vaccinating in search of their preferred brand could become a further hurdle in terms of overall rollout.
“If people start to become brand-oriented, we have another block that we have never had before,” he told Al Jazeera.
Vaccine preferences do not realize how much protection each vaccine provides
According to Research About 30 percent of people surveyed by the Kaiser Family Foundation in March said they were open about vaccinations, saying they had a strong preference for the vaccine they received, but about 25 percent had little choice.
The nonprofit found that about 24 percent of people who liked the brand said they preferred a single dose of the vaccine, while 14 percent cited efficacy levels.
Reham Awad, a pharmacy intern in the Chicago area, said he has seen all sorts of reservations and choices about the vaccine brand; Some people look for J&J shots because it is a single dose, others prefer Moderena or Pfizer because they think they have less adverse side effects.
Awabad has noticed that people have rescheduled their vaccine appointments to get the brand of their choice, which he said could return their vaccine in a “long time”.
“When people come, I always advise them to get the vaccine that is available because you never know what vaccine will be available next time,” Awd told Al Jazeera.
“You don’t know if you’re going to get the vaccine you want at a time other than these.”
Carol Osterberry, a Wayne County health officer in Michigan, voiced Awad’s concerns about the choice of vaccine brand.
Osterberry told Al Jazeera: “Vaccines are a very effective brand in preventing KVID-19 infections and diseases.
“That’s what we’re saying in the field of public health, the message is: when it’s your turn, you won’t get an appointment, don’t get vaccinated because you want one brand after another. You need to be vaccinated. “